Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 7:9:972301.
doi: 10.3389/fcvm.2022.972301. eCollection 2022.

Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics

Affiliations
Review

Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics

Lucas K Keyt et al. Front Cardiovasc Med. .

Abstract

All muscle contraction occurs due to the cyclical interaction between sarcomeric thin and thick filament proteins within the myocyte. The thin filament consists of the proteins actin, tropomyosin, Troponin C, Troponin I, and Troponin T. Mutations in these proteins can result in various forms of cardiomyopathy, including hypertrophic, restrictive, and dilated phenotypes and account for as many as 30% of all cases of inherited cardiomyopathy. There is significant evidence that thin filament mutations contribute to dysregulation of Ca2+ within the sarcomere and may have a distinct pathomechanism of disease from cardiomyopathy associated with thick filament mutations. A number of distinct clinical findings appear to be correlated with thin-filament mutations: greater degrees of restrictive cardiomyopathy and relatively less left ventricular (LV) hypertrophy and LV outflow tract obstruction than that seen with thick filament mutations, increased morbidity associated with heart failure, increased arrhythmia burden and potentially higher mortality. Most therapies that improve outcomes in heart failure blunt the neurohormonal pathways involved in cardiac remodeling, while most therapies for hypertrophic cardiomyopathy involve use of negative inotropes to reduce LV hypertrophy or septal reduction therapies to reduce LV outflow tract obstruction. None of these therapies directly address the underlying sarcomeric dysfunction associated with thin-filament mutations. With mounting evidence that thin filament cardiomyopathies occur through a distinct mechanism, there is need for therapies targeting the unique, underlying mechanisms tailored for each patient depending on a given mutation.

Keywords: ACTC1; TNNC1; TNNI3; TNNT2; TPM1; cardiomyopathy; thin filament.

PubMed Disclaimer

Conflict of interest statement

JD reports personal fees from Lexeo during the conduct of the review. EA reports personal fees from Abiomed, Novartis, Abbott, non-financial support from Astra Zeneca, personal fees from Ionis Pharmaceuticals, Sana Biotechnology, Medtronic, other from Rocket Pharmaceuticals, Papillon Therapeutics, ResQ Pharmaceuticals, personal fees from Lexeo Pharmaceuticals, Cytokinetics, Endotronics, and during the conduct of the review. MM was employed by Providence Health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Molecular structure of the cardiac sarcomere. (A) Low and (B) high magnification electron micrographs showing the sarcomeres of a cardiac myocyte in a glutaraldehyde-fixed heart from an adult male C57BL/6 mouse. (C) A magnified schematic illustrating the molecular ultrastructure of the sarcomere and demonstrating the interaction between thick filaments that act as the motor apparatus of the cell and drive contraction and thin filaments that regulate the actions of the thick filaments in response to calcium flux. Ca2+, calcium ion; TnC, troponin C; TnI, troponin I; TnT, troponin T.

References

    1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. . Contemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. (2006) 113:1807–16. 10.1161/CIRCULATIONAHA.106.174287 - DOI - PubMed
    1. Henderson CA, Gomez CG, Novak SM, Mi-Mi L, Gregorio CC. Overview of the muscle cytoskeleton. Compr Physiol. (2017) 7:891–944. 10.1002/cphy.c160033 - DOI - PMC - PubMed
    1. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. (1979) 59:689–706. 10.1161/01.CIR.59.4.689 - DOI - PubMed
    1. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. (2001) 104:1380–4. 10.1161/hc3701.095952 - DOI - PubMed
    1. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, et al. . Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. (1995) 332:1058–64. 10.1056/NEJM199504203321603 - DOI - PubMed